TY - JOUR T1 - Proton pump inhibitor use is not associated with severe COVID-19 related outcomes: A propensity score weighted analysis of a national veteran cohort JF - medRxiv DO - 10.1101/2021.07.22.21258785 SP - 2021.07.22.21258785 AU - Shailja C. Shah AU - Alese E. Halvorson AU - Brandon McBay AU - Chad Dorn AU - Otis Wilson AU - Jason Denton AU - Sony Tuteja AU - Kyong-Mi Chang AU - Kelly Cho AU - Richard L. Hauger AU - Ayako Suzuki AU - Christine M. Hunt AU - Edward Siew AU - Michael E. Matheny AU - Adriana Hung AU - Robert A. Greevy, Jr. AU - Christianne L. Roumie Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/25/2021.07.22.21258785.abstract N2 - Background and Aims Low pH deactivates most pathogens, including coronaviruses. Proton pump inhibitors (PPIs) are potent gastric acid suppressing medications. Whether PPI use vs non-use is associated with severe Coronavirus disease-2019 (COVID-19) outcomes remains uncertain. We aimed to compare severe COVID-19 outcomes between current outpatient PPI users and non-users.Methods We conducted a retrospective propensity score-weighted analysis of a national cohort of US veterans with established care who tested positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through January 9, 2021, and who had 60 days of follow-up. The positive test date was the index date. Current outpatient PPI use up to and including the index date (primary exposure) was compared to non-use, defined as no PPI prescription fill in the 365 days prior to the index date. The primary outcome was a composite of use of mechanical ventilation or death within 60 days. Weighted logistic regression models evaluated severe COVID-19 outcomes between current PPI users vs non-users.Results Of 97,674 Veterans with SARS-CoV-2 testing, 14,958 tested positive (6262 [41.9%] current PPI users, 8696 [58.1%] non-users) and comprised the analytic cohort. After weighting, all covariates were well-balanced. In the weighted cohort, there was no difference in the primary composite outcome (8.2% vs 8.0%; OR 1.03, 95% CI 0.91-1.16), secondary composite outcome, nor individual component outcomes between current PPI users and non-users. There was no significant interaction between age and PPI use on outcomes.Conclusion Among patients with SARS-CoV-2 infection, current PPI use vs non-use is not associated with severe COVID-19 outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Shah is supported by an American Gastroenterological Association Research Scholar Award (2019) and a Veterans Affairs Career Development Award (ICX002027A01). Dr. Tuteja is supported by a National Institute of Health Career Development Award (K23HL143161A01). Dr. Cho is supported by supported by Department of Veterans Affairs, Office of Research and Development, Million Veteran Program Core (#MVP000)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Veterans Affairs (VA) Tennessee Valley Healthcare system institutional review board and Research and Development Committees with a waiver of informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used for this analysis reside in the Veterans Health Administration database. Only approved VA investigators can access the data in order to inform their currently approved study proposals. The data undergo routine quality checks. These data are not and cannot be made publicly available. ER -